660 — Wai Chun Bio Technology Share Price
- HK$15.35m
- HK$184.81m
- HK$370.07m
- 27
- 78
- 29
- 40
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 1.31 | ||
Price to Sales | 0.05 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -19.68% |
Financial Summary
Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | HK$m | 579.23 | 567.55 | 1,007.19 | 773.65 | 370.07 | n/a | n/a | -5.1% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Wai Chun Bio-Technology Ltd is a Hong Kong-based investment holding company principally engaged in the manufacture and sale of modified starch. Together with its subsidiaries, the Company is principally involved in the manufacture and sale of modified starch and other biochemical products, , such as biochemical refined oil products. In addition, the Company is also involved in the trading of electronic parts, components and electrical appliances.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 1970
- Public Since
- February 5th, 1993
- No. of Employees
- 123
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
Stock Exchange of Hong Kong Limited
- Shares in Issue
- 178,476,453

- Address
- 13/F, Admiralty Centre, Tower II
- Web
- https://www.0660.hk
- Phone
- +852 null31029989
- Auditors
- McMillan Woods (Hong Kong) CPA Limited
Upcoming Events for 660
Similar to 660
Century Energy International Holdings
Stock Exchange of Hong Kong Limited
China Gas Industry Investment Holdings Co
Stock Exchange of Hong Kong Limited
Zhejiang ChangAn Renheng Technology Co
Stock Exchange of Hong Kong Limited
Changmao Biochemical Engineering Co
Stock Exchange of Hong Kong Limited
China BlueChemical
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 24:03 UTC, shares in Wai Chun Bio Technology are trading at HK$0.09. This share price information is delayed by 15 minutes.
Shares in Wai Chun Bio Technology last closed at HK$0.09 and the price had moved by +1.18% over the past 365 days. In terms of relative price strength the Wai Chun Bio Technology share price has outperformed the FTSE Developed Asia Pacific Index by +2.33% over the past year.
There is no consensus recommendation for this security.
Find out moreWai Chun Bio Technology does not currently pay a dividend.
Wai Chun Bio Technology does not currently pay a dividend.
Wai Chun Bio Technology does not currently pay a dividend.
To buy shares in Wai Chun Bio Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$0.09, shares in Wai Chun Bio Technology had a market capitalisation of HK$15.35m.
Here are the trading details for Wai Chun Bio Technology:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 660
Based on an overall assessment of its quality, value and momentum Wai Chun Bio Technology is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Wai Chun Bio Technology. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +23.15%.
As of the last closing price of HK$0.09, shares in Wai Chun Bio Technology were trading -2.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Wai Chun Bio Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Wai Chun Bio Technology's management team is headed by:
- Ching Kui Lam - CHM
- David Fenn - SEC
- Cheuk Ho Chan - NID
- Pak Man Hau - NID
- Bo Wan - NID